ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

AQST vs MPLT // ALTMAN Z-SCORE & DEBT/EQUITY

Aquestive Therapeutics Inc. (NASDAQ) VS. MapLight Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: AQST 2 — MPLT 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AQST VS. MPLT) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC AQST MPLT SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 58.30% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -32.40% -2.60 MPLT /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -10.45% — — TIE /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) -22.60% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity ACTIVE 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 2/9 +1.00 AQST /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 39.2 32.7 +6.50 AQST /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $488.2M $491.0M -$2.7M MPLT /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR AQST REV MPLT REV AQST GROSS % MPLT GROSS % AQST FCF MPLT FCF
FY 2025 $44.5M $473.4M 58.3% — -$53.0M -$138.6M
FY 2024 $57.6M $232.2M 69.0% — -$35.9M -$79.6M
FY 2023 $50.6M — — — -$6.4M —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AQST // BETA —
MPLT // BETA —